T cell and NK cells are the most promising cell types for providing treatments that could potentially offer cures to cancer and other diseases. Based on FDA guidelines, the manufacturing process for these immune cells must have high quality and controllable batch-to-batch variations in order to ensure the safety and efficacy of the "living drug."
Join a discussion with Nexcelom Bioscience, LLC on enabling novel technologies to effectively develop T and NK cell-based therapeutic products featuring our own Vanda Lopes, PhD. https://bit.ly/3nOMMYB